The global Acute Vulvovaginal Candidiasis Treatment market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The USA market for Global Acute Vulvovaginal Candidiasis Treatment market is estimated to increase from USD million in 2022 to reach USD million by 2030, at a CAGR during the forecast period of 2023 through 2030.
The China market for Global Acute Vulvovaginal Candidiasis Treatment market is estimated to increase from USD million in 2022 to reach USD million by 2030, at a CAGR during the forecast period of 2023 through 2030.
The Europe market for Global Acute Vulvovaginal Candidiasis Treatment market is estimated to increase from USD million in 2022 to reach USD million by 2030, at a CAGR during the forecast period of 2023 through 2030.
Acute vulvovaginal candidiasis is a fungal/yeast infection, which is caused by some species of Candida, especially Candida albicans. Increasing cases of vulvovaginal candidiasis can be attributed to ageing, overuse of antibiotics, diabetes, etc. Doctors are involved in prescribing medicines on the basis of their efficiency in controlling acute vulvovaginal candidiasis among the patients.
This report aims to provide a comprehensive presentation of the global market for Acute Vulvovaginal Candidiasis Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Acute Vulvovaginal Candidiasis Treatment. This report contains market size and forecasts of Acute Vulvovaginal Candidiasis Treatment in global, including the following market information:
- Global Acute Vulvovaginal Candidiasis Treatment Market Revenue, 2018-2023, 2024-2030, ($ millions)
- Global top five companies in 2022 (%)
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Clotrimazole Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Acute Vulvovaginal Candidiasis Treatment include Mycovia Pharmaceuticals, Inc, Scynexis, Inc, Basilea Pharmaceutica Ltd, Astellas Pharma Inc, Grupo Ferrer Internacional, S.A, Pacgen Life Science Corporation, NovaDigm Therapeutics, Inc, Cidara Therapeutics, Inc and Amplyx Pharmaceuticals Inc, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Acute Vulvovaginal Candidiasis Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Acute Vulvovaginal Candidiasis Treatment Market, by Type, 2018-2023, 2024-2030 ($ millions)
Global Acute Vulvovaginal Candidiasis Treatment Market Segment Percentages, by Type, 2022 (%)
- Clotrimazole
- Nystatin
- Fluconazole
- Ketoconazole
- Terbinafine
- Terconazole
- Others
Global Acute Vulvovaginal Candidiasis Treatment Market, by Application, 2018-2023, 2024-2030 ($ millions)
Global Acute Vulvovaginal Candidiasis Treatment Market Segment Percentages, by Application, 2022 (%)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Acute Vulvovaginal Candidiasis Treatment Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions)
Global Acute Vulvovaginal Candidiasis Treatment Market Segment Percentages, By Region and Country, 2022 (%)
- North America (United States, Canada, Mexico)
- Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe)
- Asia-Pacific (China, India, Japan, South Korea, Australia, Rest of APAC)
- The Middle East and Africa (Middle East, Africa)
- South and Central America (Brazil, Argentina, Rest of SCA)
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Acute Vulvovaginal Candidiasis Treatment revenues in global market, 2018-2023 (estimated), ($ millions)
- Key companies Acute Vulvovaginal Candidiasis Treatment revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
- Mycovia Pharmaceuticals, Inc
- Scynexis, Inc
- Basilea Pharmaceutica Ltd
- Astellas Pharma Inc
- Grupo Ferrer Internacional, S.A
- Pacgen Life Science Corporation
- NovaDigm Therapeutics, Inc
- Cidara Therapeutics, Inc
- Amplyx Pharmaceuticals Inc
- Pfizer, Inc.
Outline of Major Chapters:
Chapter 1: Introduces the definition of Acute Vulvovaginal Candidiasis Treatment, market overview.
Chapter 2: Global Acute Vulvovaginal Candidiasis Treatment market size in revenue.
Chapter 3: Detailed analysis of Acute Vulvovaginal Candidiasis Treatment company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Acute Vulvovaginal Candidiasis Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Acute Vulvovaginal Candidiasis Treatment Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Acute Vulvovaginal Candidiasis Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Acute Vulvovaginal Candidiasis Treatment Overall Market Size
2.1 Global Acute Vulvovaginal Candidiasis Treatment Market Size: 2022 VS 2030
2.2 Global Acute Vulvovaginal Candidiasis Treatment Market Size, Prospects & Forecasts: 2018-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Acute Vulvovaginal Candidiasis Treatment Players in Global Market
3.2 Top Global Acute Vulvovaginal Candidiasis Treatment Companies Ranked by Revenue
3.3 Global Acute Vulvovaginal Candidiasis Treatment Revenue by Companies
3.4 Top 3 and Top 5 Acute Vulvovaginal Candidiasis Treatment Companies in Global Market, by Revenue in 2022
3.5 Global Companies Acute Vulvovaginal Candidiasis Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 Acute Vulvovaginal Candidiasis Treatment Players in Global Market
3.6.1 List of Global Tier 1 Acute Vulvovaginal Candidiasis Treatment Companies
3.6.2 List of Global Tier 2 and Tier 3 Acute Vulvovaginal Candidiasis Treatment Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Acute Vulvovaginal Candidiasis Treatment Market Size Markets, 2022 & 2030
4.1.2 Clotrimazole
4.1.3 Nystatin
4.1.4 Fluconazole
4.1.5 Ketoconazole
4.1.6 Terbinafine
4.1.7 Terconazole
4.1.8 Others
4.2 By Type - Global Acute Vulvovaginal Candidiasis Treatment Revenue & Forecasts
4.2.1 By Type - Global Acute Vulvovaginal Candidiasis Treatment Revenue, 2018-2023
4.2.2 By Type - Global Acute Vulvovaginal Candidiasis Treatment Revenue, 2024-2030
4.2.3 By Type - Global Acute Vulvovaginal Candidiasis Treatment Revenue Market Share, 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Acute Vulvovaginal Candidiasis Treatment Market Size, 2022 & 2030
5.1.2 Hospital Pharmacies
5.1.3 Retail Pharmacies
5.1.4 Online Pharmacies
5.2 By Application - Global Acute Vulvovaginal Candidiasis Treatment Revenue & Forecasts
5.2.1 By Application - Global Acute Vulvovaginal Candidiasis Treatment Revenue, 2018-2023
5.2.2 By Application - Global Acute Vulvovaginal Candidiasis Treatment Revenue, 2024-2030
5.2.3 By Application - Global Acute Vulvovaginal Candidiasis Treatment Revenue Market Share, 2018-2030
6 Sights by Region
6.1 By Region - Global Acute Vulvovaginal Candidiasis Treatment Market Size, 2022 & 2030
6.2 By Region - Global Acute Vulvovaginal Candidiasis Treatment Revenue & Forecasts
6.2.1 By Region - Global Acute Vulvovaginal Candidiasis Treatment Revenue, 2018-2023
6.2.2 By Region - Global Acute Vulvovaginal Candidiasis Treatment Revenue, 2024-2030
6.2.3 By Region - Global Acute Vulvovaginal Candidiasis Treatment Revenue Market Share, 2018-2030
6.3 North America
6.3.1 By Country - North America Acute Vulvovaginal Candidiasis Treatment Revenue, 2018-2030
6.3.2 US Acute Vulvovaginal Candidiasis Treatment Market Size, 2018-2030
6.3.3 Canada Acute Vulvovaginal Candidiasis Treatment Market Size, 2018-2030
6.3.4 Mexico Acute Vulvovaginal Candidiasis Treatment Market Size, 2018-2030
6.4 Europe
6.4.1 By Country - Europe Acute Vulvovaginal Candidiasis Treatment Revenue, 2018-2030
6.4.2 Germany Acute Vulvovaginal Candidiasis Treatment Market Size, 2018-2030
6.4.3 France Acute Vulvovaginal Candidiasis Treatment Market Size, 2018-2030
6.4.4 U.K. Acute Vulvovaginal Candidiasis Treatment Market Size, 2018-2030
6.4.5 Italy Acute Vulvovaginal Candidiasis Treatment Market Size, 2018-2030
6.4.6 Russia Acute Vulvovaginal Candidiasis Treatment Market Size, 2018-2030
6.4.7 Nordic Countries Acute Vulvovaginal Candidiasis Treatment Market Size, 2018-2030
6.4.8 Benelux Acute Vulvovaginal Candidiasis Treatment Market Size, 2018-2030
6.5 Asia
6.5.1 By Region - Asia Acute Vulvovaginal Candidiasis Treatment Revenue, 2018-2030
6.5.2 China Acute Vulvovaginal Candidiasis Treatment Market Size, 2018-2030
6.5.3 Japan Acute Vulvovaginal Candidiasis Treatment Market Size, 2018-2030
6.5.4 South Korea Acute Vulvovaginal Candidiasis Treatment Market Size, 2018-2030
6.5.5 Southeast Asia Acute Vulvovaginal Candidiasis Treatment Market Size, 2018-2030
6.5.6 India Acute Vulvovaginal Candidiasis Treatment Market Size, 2018-2030
6.6 South America
6.6.1 By Country - South America Acute Vulvovaginal Candidiasis Treatment Revenue, 2018-2030
6.6.2 Brazil Acute Vulvovaginal Candidiasis Treatment Market Size, 2018-2030
6.6.3 Argentina Acute Vulvovaginal Candidiasis Treatment Market Size, 2018-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Revenue, 2018-2030
6.7.2 Turkey Acute Vulvovaginal Candidiasis Treatment Market Size, 2018-2030
6.7.3 Israel Acute Vulvovaginal Candidiasis Treatment Market Size, 2018-2030
6.7.4 Saudi Arabia Acute Vulvovaginal Candidiasis Treatment Market Size, 2018-2030
6.7.5 UAE Acute Vulvovaginal Candidiasis Treatment Market Size, 2018-2030
7 Acute Vulvovaginal Candidiasis Treatment Companies Profiles
7.1 Mycovia Pharmaceuticals, Inc
7.1.1 Mycovia Pharmaceuticals, Inc Company Summary
7.1.2 Mycovia Pharmaceuticals, Inc Business Overview
7.1.3 Mycovia Pharmaceuticals, Inc Acute Vulvovaginal Candidiasis Treatment Major Product Offerings
7.1.4 Mycovia Pharmaceuticals, Inc Acute Vulvovaginal Candidiasis Treatment Revenue in Global Market (2018-2023)
7.1.5 Mycovia Pharmaceuticals, Inc Key News & Latest Developments
7.2 Scynexis, Inc
7.2.1 Scynexis, Inc Company Summary
7.2.2 Scynexis, Inc Business Overview
7.2.3 Scynexis, Inc Acute Vulvovaginal Candidiasis Treatment Major Product Offerings
7.2.4 Scynexis, Inc Acute Vulvovaginal Candidiasis Treatment Revenue in Global Market (2018-2023)
7.2.5 Scynexis, Inc Key News & Latest Developments
7.3 Basilea Pharmaceutica Ltd
7.3.1 Basilea Pharmaceutica Ltd Company Summary
7.3.2 Basilea Pharmaceutica Ltd Business Overview
7.3.3 Basilea Pharmaceutica Ltd Acute Vulvovaginal Candidiasis Treatment Major Product Offerings
7.3.4 Basilea Pharmaceutica Ltd Acute Vulvovaginal Candidiasis Treatment Revenue in Global Market (2018-2023)
7.3.5 Basilea Pharmaceutica Ltd Key News & Latest Developments
7.4 Astellas Pharma Inc
7.4.1 Astellas Pharma Inc Company Summary
7.4.2 Astellas Pharma Inc Business Overview
7.4.3 Astellas Pharma Inc Acute Vulvovaginal Candidiasis Treatment Major Product Offerings
7.4.4 Astellas Pharma Inc Acute Vulvovaginal Candidiasis Treatment Revenue in Global Market (2018-2023)
7.4.5 Astellas Pharma Inc Key News & Latest Developments
7.5 Grupo Ferrer Internacional, S.A
7.5.1 Grupo Ferrer Internacional, S.A Company Summary
7.5.2 Grupo Ferrer Internacional, S.A Business Overview
7.5.3 Grupo Ferrer Internacional, S.A Acute Vulvovaginal Candidiasis Treatment Major Product Offerings
7.5.4 Grupo Ferrer Internacional, S.A Acute Vulvovaginal Candidiasis Treatment Revenue in Global Market (2018-2023)
7.5.5 Grupo Ferrer Internacional, S.A Key News & Latest Developments
7.6 Pacgen Life Science Corporation
7.6.1 Pacgen Life Science Corporation Company Summary
7.6.2 Pacgen Life Science Corporation Business Overview
7.6.3 Pacgen Life Science Corporation Acute Vulvovaginal Candidiasis Treatment Major Product Offerings
7.6.4 Pacgen Life Science Corporation Acute Vulvovaginal Candidiasis Treatment Revenue in Global Market (2018-2023)
7.6.5 Pacgen Life Science Corporation Key News & Latest Developments
7.7 NovaDigm Therapeutics, Inc
7.7.1 NovaDigm Therapeutics, Inc Company Summary
7.7.2 NovaDigm Therapeutics, Inc Business Overview
7.7.3 NovaDigm Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Major Product Offerings
7.7.4 NovaDigm Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Revenue in Global Market (2018-2023)
7.7.5 NovaDigm Therapeutics, Inc Key News & Latest Developments
7.8 Cidara Therapeutics, Inc
7.8.1 Cidara Therapeutics, Inc Company Summary
7.8.2 Cidara Therapeutics, Inc Business Overview
7.8.3 Cidara Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Major Product Offerings
7.8.4 Cidara Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Revenue in Global Market (2018-2023)
7.8.5 Cidara Therapeutics, Inc Key News & Latest Developments
7.9 Amplyx Pharmaceuticals Inc
7.9.1 Amplyx Pharmaceuticals Inc Company Summary
7.9.2 Amplyx Pharmaceuticals Inc Business Overview
7.9.3 Amplyx Pharmaceuticals Inc Acute Vulvovaginal Candidiasis Treatment Major Product Offerings
7.9.4 Amplyx Pharmaceuticals Inc Acute Vulvovaginal Candidiasis Treatment Revenue in Global Market (2018-2023)
7.9.5 Amplyx Pharmaceuticals Inc Key News & Latest Developments
7.10 Pfizer, Inc.
7.10.1 Pfizer, Inc. Company Summary
7.10.2 Pfizer, Inc. Business Overview
7.10.3 Pfizer, Inc. Acute Vulvovaginal Candidiasis Treatment Major Product Offerings
7.10.4 Pfizer, Inc. Acute Vulvovaginal Candidiasis Treatment Revenue in Global Market (2018-2023)
7.10.5 Pfizer, Inc. Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Acute Vulvovaginal Candidiasis Treatment Market Opportunities & Trends in Global Market
Table 2. Acute Vulvovaginal Candidiasis Treatment Market Drivers in Global Market
Table 3. Acute Vulvovaginal Candidiasis Treatment Market Restraints in Global Market
Table 4. Key Players of Acute Vulvovaginal Candidiasis Treatment in Global Market
Table 5. Top Acute Vulvovaginal Candidiasis Treatment Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Acute Vulvovaginal Candidiasis Treatment Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Acute Vulvovaginal Candidiasis Treatment Revenue Share by Companies, 2018-2023
Table 8. Global Companies Acute Vulvovaginal Candidiasis Treatment Product Type
Table 9. List of Global Tier 1 Acute Vulvovaginal Candidiasis Treatment Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Acute Vulvovaginal Candidiasis Treatment Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Acute Vulvovaginal Candidiasis Treatment Revenue, (US$, Mn), 2022 & 2030
Table 12. By Type - Acute Vulvovaginal Candidiasis Treatment Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Acute Vulvovaginal Candidiasis Treatment Revenue in Global (US$, Mn), 2024-2030
Table 14. By Application ? Global Acute Vulvovaginal Candidiasis Treatment Revenue, (US$, Mn), 2022 & 2030
Table 15. By Application - Acute Vulvovaginal Candidiasis Treatment Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Acute Vulvovaginal Candidiasis Treatment Revenue in Global (US$, Mn), 2024-2030
Table 17. By Region ? Global Acute Vulvovaginal Candidiasis Treatment Revenue, (US$, Mn), 2022 & 2030
Table 18. By Region - Global Acute Vulvovaginal Candidiasis Treatment Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Acute Vulvovaginal Candidiasis Treatment Revenue (US$, Mn), 2024-2030
Table 20. By Country - North America Acute Vulvovaginal Candidiasis Treatment Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Acute Vulvovaginal Candidiasis Treatment Revenue, (US$, Mn), 2024-2030
Table 22. By Country - Europe Acute Vulvovaginal Candidiasis Treatment Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Acute Vulvovaginal Candidiasis Treatment Revenue, (US$, Mn), 2024-2030
Table 24. By Region - Asia Acute Vulvovaginal Candidiasis Treatment Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Acute Vulvovaginal Candidiasis Treatment Revenue, (US$, Mn), 2024-2030
Table 26. By Country - South America Acute Vulvovaginal Candidiasis Treatment Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Acute Vulvovaginal Candidiasis Treatment Revenue, (US$, Mn), 2024-2030
Table 28. By Country - Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Revenue, (US$, Mn), 2024-2030
Table 30. Mycovia Pharmaceuticals, Inc Company Summary
Table 31. Mycovia Pharmaceuticals, Inc Acute Vulvovaginal Candidiasis Treatment Product Offerings
Table 32. Mycovia Pharmaceuticals, Inc Acute Vulvovaginal Candidiasis Treatment Revenue (US$, Mn) & (2018-2023)
Table 33. Mycovia Pharmaceuticals, Inc Key News & Latest Developments
Table 34. Scynexis, Inc Company Summary
Table 35. Scynexis, Inc Acute Vulvovaginal Candidiasis Treatment Product Offerings
Table 36. Scynexis, Inc Acute Vulvovaginal Candidiasis Treatment Revenue (US$, Mn) & (2018-2023)
Table 37. Scynexis, Inc Key News & Latest Developments
Table 38. Basilea Pharmaceutica Ltd Company Summary
Table 39. Basilea Pharmaceutica Ltd Acute Vulvovaginal Candidiasis Treatment Product Offerings
Table 40. Basilea Pharmaceutica Ltd Acute Vulvovaginal Candidiasis Treatment Revenue (US$, Mn) & (2018-2023)
Table 41. Basilea Pharmaceutica Ltd Key News & Latest Developments
Table 42. Astellas Pharma Inc Company Summary
Table 43. Astellas Pharma Inc Acute Vulvovaginal Candidiasis Treatment Product Offerings
Table 44. Astellas Pharma Inc Acute Vulvovaginal Candidiasis Treatment Revenue (US$, Mn) & (2018-2023)
Table 45. Astellas Pharma Inc Key News & Latest Developments
Table 46. Grupo Ferrer Internacional, S.A Company Summary
Table 47. Grupo Ferrer Internacional, S.A Acute Vulvovaginal Candidiasis Treatment Product Offerings
Table 48. Grupo Ferrer Internacional, S.A Acute Vulvovaginal Candidiasis Treatment Revenue (US$, Mn) & (2018-2023)
Table 49. Grupo Ferrer Internacional, S.A Key News & Latest Developments
Table 50. Pacgen Life Science Corporation Company Summary
Table 51. Pacgen Life Science Corporation Acute Vulvovaginal Candidiasis Treatment Product Offerings
Table 52. Pacgen Life Science Corporation Acute Vulvovaginal Candidiasis Treatment Revenue (US$, Mn) & (2018-2023)
Table 53. Pacgen Life Science Corporation Key News & Latest Developments
Table 54. NovaDigm Therapeutics, Inc Company Summary
Table 55. NovaDigm Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Product Offerings
Table 56. NovaDigm Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Revenue (US$, Mn) & (2018-2023)
Table 57. NovaDigm Therapeutics, Inc Key News & Latest Developments
Table 58. Cidara Therapeutics, Inc Company Summary
Table 59. Cidara Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Product Offerings
Table 60. Cidara Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Revenue (US$, Mn) & (2018-2023)
Table 61. Cidara Therapeutics, Inc Key News & Latest Developments
Table 62. Amplyx Pharmaceuticals Inc Company Summary
Table 63. Amplyx Pharmaceuticals Inc Acute Vulvovaginal Candidiasis Treatment Product Offerings
Table 64. Amplyx Pharmaceuticals Inc Acute Vulvovaginal Candidiasis Treatment Revenue (US$, Mn) & (2018-2023)
Table 65. Amplyx Pharmaceuticals Inc Key News & Latest Developments
Table 66. Pfizer, Inc. Company Summary
Table 67. Pfizer, Inc. Acute Vulvovaginal Candidiasis Treatment Product Offerings
Table 68. Pfizer, Inc. Acute Vulvovaginal Candidiasis Treatment Revenue (US$, Mn) & (2018-2023)
Table 69. Pfizer, Inc. Key News & Latest Developments
List of Figures
Figure 1. Acute Vulvovaginal Candidiasis Treatment Segment by Type in 2022
Figure 2. Acute Vulvovaginal Candidiasis Treatment Segment by Application in 2022
Figure 3. Global Acute Vulvovaginal Candidiasis Treatment Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Acute Vulvovaginal Candidiasis Treatment Market Size: 2022 VS 2030 (US$, Mn)
Figure 6. Global Acute Vulvovaginal Candidiasis Treatment Revenue, 2018-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Acute Vulvovaginal Candidiasis Treatment Revenue in 2022
Figure 8. By Type - Global Acute Vulvovaginal Candidiasis Treatment Revenue Market Share, 2018-2030
Figure 9. By Application - Global Acute Vulvovaginal Candidiasis Treatment Revenue Market Share, 2018-2030
Figure 10. By Type - Global Acute Vulvovaginal Candidiasis Treatment Revenue, (US$, Mn), 2022 & 2030
Figure 11. By Type - Global Acute Vulvovaginal Candidiasis Treatment Revenue Market Share, 2018-2030
Figure 12. By Application - Global Acute Vulvovaginal Candidiasis Treatment Revenue, (US$, Mn), 2022 & 2030
Figure 13. By Application - Global Acute Vulvovaginal Candidiasis Treatment Revenue Market Share, 2018-2030
Figure 14. By Region - Global Acute Vulvovaginal Candidiasis Treatment Revenue Market Share, 2018-2030
Figure 15. By Country - North America Acute Vulvovaginal Candidiasis Treatment Revenue Market Share, 2018-2030
Figure 16. US Acute Vulvovaginal Candidiasis Treatment Revenue, (US$, Mn), 2018-2030
Figure 17. Canada Acute Vulvovaginal Candidiasis Treatment Revenue, (US$, Mn), 2018-2030
Figure 18. Mexico Acute Vulvovaginal Candidiasis Treatment Revenue, (US$, Mn), 2018-2030
Figure 19. By Country - Europe Acute Vulvovaginal Candidiasis Treatment Revenue Market Share, 2018-2030
Figure 20. Germany Acute Vulvovaginal Candidiasis Treatment Revenue, (US$, Mn), 2018-2030
Figure 21. France Acute Vulvovaginal Candidiasis Treatment Revenue, (US$, Mn), 2018-2030
Figure 22. U.K. Acute Vulvovaginal Candidiasis Treatment Revenue, (US$, Mn), 2018-2030
Figure 23. Italy Acute Vulvovaginal Candidiasis Treatment Revenue, (US$, Mn), 2018-2030
Figure 24. Russia Acute Vulvovaginal Candidiasis Treatment Revenue, (US$, Mn), 2018-2030
Figure 25. Nordic Countries Acute Vulvovaginal Candidiasis Treatment Revenue, (US$, Mn), 2018-2030
Figure 26. Benelux Acute Vulvovaginal Candidiasis Treatment Revenue, (US$, Mn), 2018-2030
Figure 27. By Region - Asia Acute Vulvovaginal Candidiasis Treatment Revenue Market Share, 2018-2030
Figure 28. China Acute Vulvovaginal Candidiasis Treatment Revenue, (US$, Mn), 2018-2030
Figure 29. Japan Acute Vulvovaginal Candidiasis Treatment Revenue, (US$, Mn), 2018-2030
Figure 30. South Korea Acute Vulvovaginal Candidiasis Treatment Revenue, (US$, Mn), 2018-2030
Figure 31. Southeast Asia Acute Vulvovaginal Candidiasis Treatment Revenue, (US$, Mn), 2018-2030
Figure 32. India Acute Vulvovaginal Candidiasis Treatment Revenue, (US$, Mn), 2018-2030
Figure 33. By Country - South America Acute Vulvovaginal Candidiasis Treatment Revenue Market Share, 2018-2030
Figure 34. Brazil Acute Vulvovaginal Candidiasis Treatment Revenue, (US$, Mn), 2018-2030
Figure 35. Argentina Acute Vulvovaginal Candidiasis Treatment Revenue, (US$, Mn), 2018-2030
Figure 36. By Country - Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Revenue Market Share, 2018-2030
Figure 37. Turkey Acute Vulvovaginal Candidiasis Treatment Revenue, (US$, Mn), 2018-2030
Figure 38. Israel Acute Vulvovaginal Candidiasis Treatment Revenue, (US$, Mn), 2018-2030
Figure 39. Saudi Arabia Acute Vulvovaginal Candidiasis Treatment Revenue, (US$, Mn), 2018-2030
Figure 40. UAE Acute Vulvovaginal Candidiasis Treatment Revenue, (US$, Mn), 2018-2030
Figure 41. Mycovia Pharmaceuticals, Inc Acute Vulvovaginal Candidiasis Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Scynexis, Inc Acute Vulvovaginal Candidiasis Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Basilea Pharmaceutica Ltd Acute Vulvovaginal Candidiasis Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Astellas Pharma Inc Acute Vulvovaginal Candidiasis Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Grupo Ferrer Internacional, S.A Acute Vulvovaginal Candidiasis Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Pacgen Life Science Corporation Acute Vulvovaginal Candidiasis Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. NovaDigm Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Cidara Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Amplyx Pharmaceuticals Inc Acute Vulvovaginal Candidiasis Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Pfizer, Inc. Acute Vulvovaginal Candidiasis Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
